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Abstract 
Context   In advanced cancer, abnormal sleep patterns may contribute to poor 
quality of life but the impact of opioid related sleep disorders has not been 
explored in detail in these patients. 
Objective   To document sleep and respiratory patterns in patients with cancer, 
receiving a range of opioids, determine factors that contribute to severity of 
central or obstructive apnoea and to what extent these contribute to sleep 
disturbance. 
Methods   Adults with advanced cancer admitted to a palliative care service 
underwent a sleep analysis by an unattended polysomnograph.  Total sleep time, 
apnea hypopnea index (AHI), central apnea index (CAI), obstructive apnoea 
hypopnea index OAHI), arousal index (AI) and oxygen desaturation were 
measured.  Baseline assessment included body habitus, Mallampati score, 
comorbidity indices, concomitant medications and the Berlin questionnaire. 
Epworth sleepiness scale, Stanford Sleepiness scale and Wu cancer fatigue scales 
were documented 
Results   28 patients were studied, including 25 receiving opioids.   In the latter 
group, the AHI was mildly abnormal in 6 patients and severely abnormal in 10 
patients. CAI and OAHI were abnormal in 9 and 17 patients respectively.  There 
was no significant correlation between opioid dose and polysomnographic 
results. Conclusion   In patients with advanced cancer receiving opioid 
analgesia, there was a high prevalence of respiratory disturbance, both central 
and obstructive, and deranged sleep patterns. Addressing sleep disordered 
breathing in cancer patients  has the potential to improve day-time drowsiness 
and quality of life. 
 
 
 
Keywords 
Cancer, palliative care, respiratory disturbance, sleep apnea, quality of life 
 
Introduction 
 
Sleep disturbance in patients with advanced cancer has been identified as a 
significant contribution to symptom burden and is often poorly treated (1).  The 
mechanisms are complex and include pain, anxiety, depression, medications, and 
gastrointestinal disorders.  Sleep studies may be used to define the nature of 
disordered sleep in an attempt to identify aspects that are amenable to therapy.  
 
Sleep disordered breathing (SDB) is the repeated interruption of ventilation 
during sleep leading to arousal or partial arousal and oxygen desaturation (2). 
Obstructive sleep apnoea is related to the repetitive or partial collapse of the 
pharyngeal airway leading to hypoxia, and has an incidence of 5-34% in the 
general population (3,4).   Central sleep apnoea reflects a reduced response to 
hypercapnia in central chemoreceptors and is associated with a lack of rib cage 
and abdominal expansion. It is rare, with an  incidence in the general population 
probably less than 1% (5).  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
The adverse impact of long term opioids on sleep patterns in adults without 
cancer has been well demonstrated (6,7), but little is known about shorter term 
use in the palliative care setting.  Abnormal sleep/wake patterns have been 
documented in patients with advanced solid tumours with reduced quantity and 
quality of nocturnal sleep and episodes of sleep occurring during the day (8). 
Almost three-quarters of the patients were receiving opioid therapy but the 
effect on breathing patterns was not explored. 
 
It is thought that respiratory depression secondary to opioid use is not a 
common problem encountered in palliative care clinical practice when opioids 
are carefully titrated to control pain (9).  Whilst respiratory depression in 
patients on opioids is rarely seen during the day, concern has been expressed 
that it may be more common than previously recognised at night during sleep, 
with consequent adverse effects on quality of life. In a previous case series from 
this group, two of three women with metastatic breast cancer on high dose 
opioids who underwent sleep studies were shown to have severe central sleep 
apnoea (10). 
 
The literature suggests that central apnoea is a common complication of chronic 
opioid therapy in adults without cancer, affecting between 30-90% of patients 
(11-13). Moreover, it can be reversed following opioid withdrawal (14). Most 
studies have been carried out in patients on methadone maintenance programs 
or from patients referred to sleep disorder clinics.  The distinguishing sleep 
disordered features in patients receiving opioid medications include greater 
severity of disturbance during non REM compared to REM sleep and 
ineffectiveness of nasal CPAP (15). The effect may be dose related (13,16), but in 
the palliative care setting, opioid dose reduction may not be feasible. 
 
In addition to central apnoea, opioids may cause or exacerbate obstructive sleep 
apnoea. This has been demonstrated in patients on methadone maintenance 
programmes where the effect was not clearly related to dose (17).  
 
The present study was designed to assess the prevalence of sleep disordered 
breathing in a series of patients with malignant disease, the majority of whom 
were on chronic opioid therapy. Polysomnography was used to determine the 
frequency of central and obstructive sleep apnoea and any correlation with 
medications, diagnosis or co-morbid conditions.  
 
 
 
 
Patient and Methods 
 
Eligible patients were those with malignant disease admitted to Mater Health 
Services, Brisbane, known to the palliative care service, having no change in 
opioid dose during the preceding 48 hours, willingness to undergo a formal sleep 
study whilst an in-patient, and the ability to give fully informed written consent.  
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Exclusion criteria comprised; acutely unwell (eg sepsis, pulmonary embolus, 
myocardial infarction), unstable medical condition/symptoms that that would 
prevent compliance with all trial requirements, resting oxygen saturation levels 
<90% on room air, chest infection, acute exacerbation of COPD or asthma or 
other reversible pulmonary disease and any known sleep disordered breathing. 
 
Baseline assessment 
 
Participants provided a detailed medical history including respiratory illnesses, 
co-morbidities and sleep pattern followed by a physical examination. 
Demographics collected at baseline included; age, sex, malignant diagnosis, date 
of diagnosis, height and weight.  Comorbidities were assessed using the Charlson 
Comorbidity index,  the New York Heart Association (NYHA) Classification and 
the Australian – modified Karnofsky Performance Status (AKPS) (18,19).    Also 
documented were: opioid dose (oral morphine equivalent (OME)) (20) and 
duration of use, concomitant medications such as benzodiazepines or other 
sleeping tablets, cigarette and alcohol use. 
 
The anatomy of the oral cavity; specifically, the visibility of the base of uvula, 
faucial pillars (the arches in front of and behind the tonsils) and soft palate was 
examined pre-sleep test to determine a Mallampati score (21). A high Mallampati 
score (class 4) is associated with a higher incidence of obstructive sleep apnoea. 
Other factors that might predispose to sleep apnoea assessed included Body 
Mass Index (BMI), neck circumference and the Berlin Questionnaire (22).  This 
10-item questionnaire enquires about snoring behaviour, wake time sleepiness 
or fatigue, and the presence of obesity or hypertension in 3 categories. A positive 
result in 2 or more categories equates with a chance of apnoea.   
 
A number of assessments were undertaken to measure the possible adverse 
effect of sleep disturbance on overall quality of life. The Epworth Sleepiness 
Scale (23) is a self- administered questionnaire that provides a measurement of 
the patients’ general level of daytime sleepiness. It scores the chance of sleep in a 
number of situations (eg watching television) on a scale from 0-3. A total score of 
>10 is consistent with abnormal day-time sleepiness. The Stanford Sleepiness 
Scale (24) is a 7-point self-rating scale used to quantify progressive steps in 
sleepiness from “wide awake” to “sleep onset soon”. The Wu Cancer Fatigue 
Scale (25) is a nine question, five point scale, with a range of possible scores from 
five to 45. The lower the score,  the better the fatigue. 
  
Participants completed the Hospital Anxiety and Depression Scale (HADS) (26) 
 - a 14-item scale, with seven items measuring anxiety (HADS-A) and seven 
measuring depression (HADS-D). Scores range from 0 to 21 for each scale, higher 
numbers represent more distress.   
 
Study procedure 
 
A Somté  (Compumedics, Melbourne, Australia) unattended polysomnogram was 
performed at the patient’s ward bedside. The device was  set up in the evening 
and taken down in the morning by a member of the Sleep Unit or the nurse who 
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was looking after the patient.  Patient observations could be carried out during 
the night if required without interfering with data. A minimum of eight hours 
data collection was considered ideal for optimal data analysis. Overnight staff in 
the sleep disorders unit responded to any queries from the ward staff and a sleep 
physician was available on call. 
 
The results were scored manually according to standard techniques (27). Of 
particular interest were:  total sleep time, arousal index, total apnea hypopnea 
index (AHI), central apnoeic index (CAI), obstructive apnoeic hypnoea index 
(OAHI) and oxygen desaturation index (ie % time where Hb-O2 saturation is < 
90%). The definition of central versus obstructive events and apnoea vs 
hypopnea were according to standard criteria (27).  An AHI greater than 5 per 
hour was regarded as abnormal  
 
Sample size and Analysis. 
It was planned to include three groups of approximately ten patients participants 
per group: 
-  patients on high dose opioid >200mg/day OME 
-  patients on moderate dose opioid ≥40 - 200mg/day OME 
-  patients on low dose (<40mg OME/day)/no opioid therapy  
 
Statistical analysis   
Frequencies and descriptive statistics were determined for all variables based on 
the type of measure.  The prevalence of sleep apnoea overall, and by group, was 
determined.  Bivariate analyses (correlations or chi-square tests) was tested for 
associations between central sleep or obstructive apnoea and potential 
predictors. Simple logistic regression analyses was used to assess the 
relationship between sleep apnoea and each of the potential predictors, and also 
the opioid dose, for the entire sample.    
 
Results 
 
Sleep studies were performed on 28 patients (19 male), 25 of whom were 
receiving regular opioid medications. Of these, 14 were on fentanyl transdermal 
(1 plus methadone, 1 plus morphine), 9 on oxycodone (1 plus morphine), 1 on 
hydromorphone, 1 on methadone, morphine and oxycodone.  
 
Participants had a range of malignancies, most commonly prostate (7), 
genitourinary (4) and lung (3).  The median age and performance status was 72 
years (range 43 -91) and 60 (range 40-90). The median BMI was within the 
healthy population BMI range at 24.5 (range 17.3 - 35.1).  
 
Total sleep time ranged from 3.1 to 9.9 hrs (median 6.5 hr). Overall, 7 of 28 had 
no evidence of any sleep disturbance. Of the 3 participants not on opioids, 1 sleep 
study was normal and 2 were moderately abnormal (AHI 10 and 18). CAI was 
normal in all those not receiving opioids. The patterns of abnormalities are 
shown in Table 1.      
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In patients receiving opioids, two patients had an abnormal CAI only, 12 OHAI 
abnormalities and 7 demonstrated a mixed pattern. The severity of 
abnormalities in 9 patients with CAI >5 events /hr ranged from 7-126.  In 8 of 
these the OAHI was also abnormal.   OAHI was greater than 5 events/hr in 18 
patients. Four were severe and exceeded 30 events/hr. Two of the latter had 
concurrent abnormalities in CAI.  The total AHI ranged from 0-129 events/hr 
(median 16.5).   Ten patients had an AHI >30 events/hr. Arousal index was 
outside the normal range of 10-25 in 11 cases and exceeded 50 in 6 patients. 
The percentage time that oxygen saturation fell below 90 ranged from 0-95% 
(median 8%).  In 6 patients this was for more than 50% of the observation time. 
 
When analysed with regard to OME in 24 hours grouped into low (0-40, medium 
(40-200 and high dose (>200,) there was no overall correlation with AHI, CAI or 
OAHI. The Arousal Index was not influenced by OME. 
 
The Mallampatti score was 1 in most patients. The OAHI in 3 patients with scores 
over 3 were all high - 107, 23, and 22 events/hr respectively, however a low 
Mallampatti score did not exclude an abnormal result. Twelve participants had a 
high risk of apnoea from the Berlin questionnaire. 
 
With regard to sleepiness and fatigue measures, the Epworth Sleepiness Score 
was abnormal (>10) in 10 patients, Stanford Sleep Scale was 2 or less 
(suggesting full alertness) in 6 patients. The Wu index was over 20, suggestive of 
considerable fatigue, in 12 patients.  On HAD scoring, 7 participants 
demonstrated significant anxiety and 8 significant depression (scores>7).   None 
of these outcomes appeared have a significant correlation with any of the 
polysomnographic data.  
 
Similarly, there was no correlation with any of the other variables measured ie 
co-morbidities, concomitant medications or other sleeping tablets, cigarette and 
alcohol use. 
 
Discussion 
 
In this study the majority of patients with advanced cancer had evidence of sleep 
disordered breathing as reflected by an abnormally high AHI. The patterns 
observed were consistent with apnoea that was predominantly obstructive in 
nature, and less frequently central in origin or a mixture of the two. In the 3 cases 
previously reported by Hardy et al (10), one patient had severe central apnoea 
(121 episodes/hour) a level that was observed in only one participant in the 
present series. The second patient also had severe central apnoea, but this was 
combined with a moderate obstructive element.  
 
Disturbed sleep in patients with cancer has been widely reported (28) and the 
adverse impact of sleep disturbance on the quality of life of patients receiving 
palliative care has been emphasised (29).  In a recent study using ambulatory 
polysomnography in 114 patients with cancer (8), 17% achieved less than 5 
hours sleep per night. A curvilinear relationship has been demonstrated between 
mortality and sleep in patients with advanced cancer (30). Seventy-three of the 
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sample population were receiving opioid medication and this was associated 
with a small but significant increase in Stage 2 REM sleep. No other specific sleep 
characteristics were noted with opioids whereas serotonin uptake inhibitors and 
beta blockers were both associated with reduced sleep time and beta blockers 
also increased daytime REM sleep. No attempt was made to evaluate the possible 
contribution of apnoea to sleep disturbance in this study. 
 
Sleep disordered breathing associated with long term opioid therapy in adults 
without cancer has also been widely reported (11,13) although the precise 
nature of such disorders has not been clearly defined. A recent systematic review 
(31) suggested that opioids were associated with a moderately increased risk of 
central, but not obstructive, apnoea.  In contrast, a study in adults receiving 
methadone, observed obstructive apnoea to be the dominant abnormality (17). 
In the 71 patients studied, 35% had OSA and 14% CSA.   
 
There are fewer data on the acute or short term use of opioids, particularly in the 
palliative care setting, where formal evaluation using polysomnography is likely 
to be impractical and access to sleep laboratory expertise difficult. In a study of 
healthy volunteers, 42 subjects received either placebo, sustained release 
morphine (15mg) or methadone (5 mg). This was a double blind crossover study 
over three consecutive nights (32).  Total sleep time was not altered. Both drugs 
reduced arousal index and to a significant extent with methadone. There was no 
difference in OAHI between the three groups.  The adverse effects of oral and 
intravenous opioids on breathing during sleep and sleep architecture also has 
been demonstrated in healthy adults (33,34). 
 
The influence of opioids on both breathing rhythm and control of ventilation may  
increase the risk of central sleep apnoea.  Obstructive sleep apnoea may also be 
exacerbated by opioids due to relaxation of pharyngeal tone and increased 
airway collapsibility (35).   In view of the potential impact of sleep disordered 
breathing   on both physical and psychological morbidity, it would seem 
appropriate to consider whether, particularly in those patients under palliative 
care who are not at end of life and who may have a longer life expectancy, are 
screened to anticipate potential sleep problems.  In the present study a number 
of possible predictive factors were evaluated, but none were associated with 
sleep disordered breathing, possibly because of the relatively small sample size.  
 
Continuous Positive Airways Pressure (CPAP) has been shown to be of benefit in 
obstructive apnoea but may not assist central apnoea. A more complicated ‘servo 
controlled ‘technique has been recommended to assist ventilation in this 
condition (16,36).  Simpler measures include oral appliances fitted by 
orthodontists and worn at night, that move the tongue and mandible forward 
thus enhancing airway patency (37). 
 
The major limitation of this study was the small sample size. This meant there 
was potential for sample bias, selection bias, and limited ability to empirically 
evaluate covariates. It was also limited by the fact that polysomnography was not 
performed on a larger number of patients not receiving opioids. As baseline 
polysomnography data prior to initiation of opioid therapy was not available, it 
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is difficult to conclude unequivocally whether the findings are due to opioid 
therapy or other characteristics of these patients with advanced cancer.  
 
In conclusion, this study has confirmed a high prevalence of sleep disturbance 
and sleep disordered breathing in this set of patients with advanced cancer. 
Further research is needed to define the effect of advanced cancer and opioid 
usage on sleep disorders. This will help to guide future interventional studies 
aimed at improving quality of life. 
 
 
 
 
 
Disclosure/Conflict of Interest: 
All of the authors have nothing to disclose. 
 
Acknowledgements: 
We would like to acknowledge Queensland Sleep for performing the sleep 
studies. 
 
Funding: 
This research did not receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9
 
References 
 
1)  Yennurajalingam S, Tayjasanant S, Balachandran D, et al   Association 
between daytime activity, fatigue, sleep, anxiety, depression, and symptom 
burden in advanced cancer patients: A preliminary report. J Palliat Med 2016 
;19:849-856. 
 
2)  Dempsey JA, Veasey SC, Morgan BJ,et al. Pathophysiology of sleep apnea. 
Physiol Rev.2010; 90:797-8. 
3)  Lee W, Nagubadi S, Kryger, MH et al. Epidemiology of obstructive sleep apnea: 
A population-based perspective. Expert Rev Respir Med 2008 ;2: 349-364 
 
4)   Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM Increased 
prevalence of sleep-disordered breathing in adults. Am J Epidemiol 
2013;177(9):1006–14 
 
5) Orr JE, Malhotra A, Sands SA. Pathogenesis of central and complex sleep 
apnoea. Respirology 2017 ;22:43-52. 
 
6)  Hassamal, S, Miotto K,, WangT,et al   A narrative review: The effects of opioids 
on sleep disordered breathing in chronic pain patients and methadone 
maintained patients.  Am J Addict, 2016; 25: 452-465 
 
7)  Panagiotou I, Mystakidou K. Non-analgesic effects of opioids: opioids’ effects 
on sleep. Curr Pharm Des 2012;18:6025-6033 
 
8)  Parker KP, Bliwise DL, Ribeiro M, et al    Sleep/Wake Patterns of Individuals 
with Advanced Cancer Measured by Ambulatory Polysomnography. 
J Clin Oncol 2008;26:2464-2472 
 
9)  Currow DC, Ward AM, Abernethy AP (2009). Advances in the pharmacological 
management of breathlessness. Curr Opin Support Palliat Care; 3: 103-106 
 
10)  Hardy J, Bowler S . Central sleep apnoea in cancer patients on opioids. J Pain 
Symptom Management 2010; 40: e3-e5 
 
11)  Farney RJ, Walker JM, Coward TV et al . Sleep-disordered breathing 
associated with long-term opioid therapy. Chest, 2003;123;632-639 
 
12)  Wang D Teichtahl H, Drummer O, et al. Central sleep apnea in stable 
methadone maintenance treatment patients. Chest 2005; 128:1348-1356 
 
13)  Walker JM, Farney RJ, Rhondeau S, et al . Chronic opioid use is a risk factor 
for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 
2007; 3:455-461 
 
14)  Ramar K. Reversal of sleep disordered breathing with opioid withdrawal. 
Pain Pract 2009;9;394-398 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10 
 
15)  Zutler M, Holty JE. Opioids, sleep, and sleep-disordered breathing. Curr 
Pharm Des.2011;17: 1443-1449 
 
16)  Javaheri, S, Athar Malik, Smith, J et l.. Adaptive pressure support 
servoventilation: a novel treatment for sleep apnea associated with use of 
opioids. J Clin Sleep Med 2008;4: 305-310 
 
17)  Sharkey, KM, Kurth, MD, Andersen, BJ et al  Obstructive sleep apnea is more 
common than central sleep apnea in methadone maintenance patients with 
subjective sleep complaints. Drug Alcohol Depend 2010;108:77-83. 
 
20)  Australian College of Rural and Remote Medicine (2014) GP Pain Help. 
Centre for Palliative Care Research and Education. Available from 
http://www.gppainhelp.com/Dose_Conversion.html.  ( Accessed 20June 2017) 
 
21)  Nuckton TJ, Glidden DV, Browner et al. Physical examination: Mallampati 
score as an independent predictor of obstructive sleep apnea. Sleep 
2006;29:903-908 
 
22)  Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin 
Questionnaire to identify patients at risk for the sleep apnea syndrome  .Ann 
Intern Med 1999;131:485-91 
 
18)  Groot V, Beckerman H, Landhorst G, Bouter L. How to measure comorbidity: 
a critical review of available methods. J Chron Dis. 1987;40:373-83. 
 
19)  Abernethy, AP, Shelby-James T, Fazekas B, Woods D, Currow DC. The 
Australian-modified Karnofsky Performance Status (AKPS) scale: a revised scale 
for contemporary palliative care clinical practice. BMC Palliat Care 2005;4:7. 
doi:10.1186/1472-684X-4-7 
 
23)  Johns MW. A New Method for Measuring Daytime Sleepiness: Epworth 
Sleepiness Scale.. Sleep 1991; 14: 540-545. 
 
24)  Hoddes E, Zarcone V, Smythe H et al. Quantification of Sleepiness; a new 
approach.  Psychophysiology 1973;10:431-436. 
 
25)  Wu H, Wyrwich K, McSweeney M. Assessing fatigue in persons with cancer: 
further validation of the Wu Cancer Fatigue Scale. J Pain Symptom Manage 
2006;32:255-265. 
 
26)  Zigmond AS, Snaith RP. The hospital anxiety and depression scale.  Acta 
Psychiatr Scand 1983;67:361-70 
 
27) Iber C, Ancoli Israel S, Chesson Jr A, Quan S The AASM manual for the scoring 
of sleep and associated events. Westchester, IL: Am Acad Sleep Med. 2007. 
28)   Sheely LC. Sleep disturbances in hospitalized patients with Cancer. 
Oncology Nursing Forum 1996; 23: 109-111 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
 
29)  Hajjar RR. Sleep disturbance in palliative care. Clinics in geriatric medicine. 
2008 Feb 29;24(1):83-91. 
 
 
30)  Collins KP, Geller DA, Antoni M, Donnell DM et al. Sleep duration is 
associated with survival in advanced cancer patients  Sleep Med. 2017;3:208-212 
 
31)  Filiatrault, ML, Chauny, JM, Daoust, R et al.  Medium increased risk for 
central sleep apnea but not obstructive sleep apnea in long-term opioid users: A 
systematic review and meta-analysis. J Clin Sleep Med 2016; 12: 617-625 
 
32)  Drimsdale, JE. Norman, D. DeJaAHIn, D et al. The effect of opioids on sleep 
architecture. J Clin Sleep 2007 Med; 3 :33-36 
 
33)  Robinson RW, Zwillich CW, Bixler EO et al. Effects of oral narcotics on sleep-
disordered breathing in healthy adults. Chest 1987;91:197-203. 
 
34)  Shaw IR, Lavigne G, Mayer, P et al. Acute intravenous administration of 
morphine perturbs sleep architecture in healthy pain-free young adults: a 
preliminary study. Sleep 2005 ;28:677-82 
 
35)  Pattinson, KTS. Opioids and the control of respiration. Br J Anaesth 2008; 
100 :747-58  
 
36)  Reddy R, Adamo D, Kufel T et al . Treatment of opioid-related central sleep 
apnea with positive airway pressure: a systematic review. J Opioid Manag 2014; 
10: 57-62 
 
37)  Norman D, Loredo JS. Obstructive sleep apnea in older adults. Clin Geriatr 
Med.2008;24:151-65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table1.   Results of Polysomnography  
 
OME Total 
Sleep 
Time 
CAI 
Events/h 
OAHI 
Events/h 
AHI 
Events/h 
AI 
Events/h 
%Time 
Sa02<90% 
270 7.4 9 1 9.5 11.4 0 
135 6.9 1 1 2 1.2 0.2 
270 9 0 1 1.8 16 5 
135 6.2 1 107 108 102 37 
160 6.1 35 20 54 29 27.2 
80 8.9 0.3 0.5 2.5 4.4 0.2 
877 9.7 1.4 6.4 7.9 19.7 0.2 
510 6.8 0 16.8 16.8 19.6 11 
1110 4.9 25.9 22.9 48.8 59.7 95.8 
1150 6 0 0 1.5 11 0.1 
180 8.5 15.8 22.5 38.3 37.6 - 
40 9.8 0 0 0 26.4 8.4 
135 7.8 0.5 34.8 35.3 22.9 0 
1970 7.8 42.9 28.9 71.7 51 - 
60 6.7 1 11.6 12.7 14.6 0 
200 6.9 0 16.4 16.6 26.2 54.2 
135 7.2 1.8 52.8 55 53 24 
580 4.8 0 0 0 4.6 0 
30 6.6 4.4 13.55 18 21.6 10 
560 4.1 8.6 5.2 13.8 5.7 0.2 
200 8.9 2.6 113.28 115.9 107.1 95 
0 5.9 0 17.56 17.56 24.7 20 
0 3.05 0 2.3 2.3 12.5 - 
225 9.9 126.3 2.34 128.6 44 9 
387 9 26.8 11 37.8 39 4 
20 3.1 0 15.36 15.36 15 0.4 
0 3.2 7.2 9.6 116.8 56.9 2.5 
313 6.33 0 6.95 6.95 11.8 25 
 
OME = Oral morphine equivalent mg/24 hours  
CAI = Central Apnoea Index 
OAHI = Obstructive Apnoea Hypopnoea Index 
AHI = Apnea Hypopnea Index 
AI = Arousal Index  
 
Abnormal results in bold. 
 
 
 
 
 
 
 
 
